Document Classification

Section Type: METHODS

Text: Patients with a favourable decline in human chorionic gonadotropin and alfa-fetoprotein continued BEP (Fav-BEP group) for 3 additonal cycles, whereas patients with an unfavourable decline were randomly assigned (1:1) to receive either BEP (Unfav-BEP group) or a dose-dense regimen (Unfav-dose-dense group), consisting of intravenous paclitaxel (175 mg/m (2) over 3 h on day 1) before BEP plus intravenous oxaliplatin (130 mg/m (2) over 3 h on day 10 ; two cycles), followed by intravenous cisplatin (100 mg/m (2) over 2 h on day 1), intravenous ifosfamide (2 g/m (2) over 3 h on days 10, 12, and 14), plus mesna (500 mg/m (2) at 0, 3, 7 and 11 h), and bleomycin (25 units per day, by continuous infusion for 5 days on days 10-14 ; two cycles), with granulocyte-colony stimulating factor (lenograstim) support.